ISCIII (Institute of Health Carlos III), under Spanish Ministry of Science and Innovation, has launched an extraordinary funding call for proposals on SARS-CoV-2 and Covid-19 research projects with a budget of €24M. BioAssays, in its commitment to the fight against the emerging SARS-CoV-2 coronavirus, submits a proposal for this call, contributing with all its knowledge, expertise and technologies, for the development of fast and reliable diagnostic kits for SARS-CoV-2 detection to address the current Covid-19 outbreak and even future coronavirus outbreaks.
Committed to the fight against the emerging SARS-CoV-2 coronavirus, responsible for the ongoing pandemic of Covid-19, designated Public Health Emergency of International Concern, BioAssays submits a proposal for 21stIMI2 (Innovative Medicines Initiative) call, with a budget of €45M, for the “Development of therapeutics and diagnostics combatting coronavirus infections” within the European Horizon 2020 programme. BioAssays contributes with all its knowledge, expertise and technologies, for the development of fast and reliable diagnostic kits for not only current SARS-CoV-2 outbreak, but also future possible coronavirus outbreaks.
BioAssays increases its R+D+i lines with Hombiocat project, focused on the fabrication of biocatalysts for renewable feedstocks exploitation.
BioAssays has been funded by CDTI as national agent of the European Commission for the EraNet Co-Biotech Programme (Horizon 2020) to execute the activities that BioAssays leads and participates together with other 4 European academic groups for the development of biocatalysts for amino acid production from renewable feedstocks.
Thanks to this project, BioAssays consolidates its trajectory as R+D+i company in Biotechnology.
Thanks to the EraNet Co-Biotech programme of the European Horizon 2020, BioAssays increases its R+D+i with the development of biocatalysts for the production of amino acids from renewable sources.
The Hombiocat project in which BioAssays participates together with other 4 European academic groups has been selected for funding by the European Commission in the 2017 EraNet Co-Biotech call.
BioAssays strengthens its R+D+i in animal vaccines development through the “2016 NEOTEC” call.
BioAssays has been funded by the Centro de Desarrollo Tecnológico Industrial (CDTI) through the call “NEOTEC 2016” for R+D+i projects aimed to develop a prophylactic and safe vaccine against the ASFV (African Swine Fever Virus)
Thanks to this project, BioAssays strengthens its trajectory as R+D+i company in Biotechnology.
BioAssays strengthens its R+D+i in Molecular Diagnosis of viral infections through the EMPLEA 2014 call.
BioAssays has been funded by the Ministerio de Economía y Competitividad through the EMPLEA 2014 call for the development of molecular tools in the diagnosis of viral infections.
Thanks to this project, BioAssays starts its R+D+i career in Spanish Biotechnology.
BioAssays opens its first Molecular and Cell Biology laboratory at Parque Científico de Madrid (www.FPCM.es).